Search bioRxiv⌕ Search

Biology subjects

Godfrey, L. K.

Publications and source records attributed to Godfrey, L. K..

2 recordsLinked to original sources

pyfraglib: An integrated cfDNA fragmentomics platform

SummaryCell-free DNA (cfDNA) fragmentomics is the analysis of a diverse set of cfDNA fragment features, e.g. fragment length profiles, windowed protection scores, and end motifs. As such it requires software tooling for fragment extraction, statistical feature modeling, and cohort-level comparative analysis. In silico simulations can facilitate the development and validation of new methods by generating testing datasets with known ground truth. Existing tools address individual aspects of this workflow but none provide all necessary capabilities within a single package. ResultsWe present pyfraglib, a platform integrating fragment extraction from short- and long-read sequencing, statistical feature modeling (Gaussian mixture and NMF decomposition of fragment length profiles, end motif diversity, windowed protection scores), cohort-level differential testing of said features, and a simulation module. The library is exposed through a command-line interface, a Python API, and a Nextflow pipeline. We demonstrate pyfraglib in two ways. First, on two simulated 20-sample cohorts we show that pyfraglibs per-sample and cohort-level analyses recover the differences introduced by construction. Second, we apply pyfraglib to 88 cfDNA samples from a central nervous system lymphoma (CNSL) study and construct a fragmentomics score combining an NMF signature with end motif and WPS summaries via a classifier trained on cerebrospinal fluid and healthy donor plasma samples. As a proof of concept and applied to 66 baseline patient plasma samples, the score identifies a high-risk subgroup with worse failure-free survival (log-rank p=0.0247). Conclusionspyfraglib integrates sample- and cohort-level fragmentomics analyses as well as in silico simulation within a consistently engineered Python framework. pyfraglib source code and documentation are available at https://github.com/schwarzlab-ccb/pyfraglib.

bioinformatics↗

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. Drug resistance is the major cause for therapeutic failure in PDAC patients with progressive disease. The mechanisms underlying resistance formation are complex and remain poorly understood. To gain insights into molecular changes during the formation of resistance to oncogenic MAPK pathway inhibition we utilized short-term passaged primary tumor cells from ten PDACs of genetically engineered mice. We followed gain and loss of resistance upon MEKi exposure and withdrawal by longitudinal integrative analysis of whole genome sequencing, whole genome bisulfite sequencing, RNA-sequencing and mass spectrometry data. We found that resistant cell populations under increasing MEKi treatment evolved by the expansion of a single clone but were not a direct consequence of known resistance-conferring mutations. Rather, resistant cells showed adaptive DNA hypermethylation of 209 and hypomethylation of 8 genomic sites, most of which overlap with regulatory elements known to be active in murine PDAC cells. Both DNA methylation changes and MEKi resistance were transient and reversible upon drug withdrawal. The effector caspase CASP3 is one of the 114 genes for which transcriptional downregulation inversely correlated with the methylation status of the associated DNA region. CASP3 inactivation in resistant cells led to attenuation of drug-induced apoptosis which could be reversed by DNA methyltransferase inhibition with remarkable sensitivity exclusively in the resistant cells. Overall, our data provide a context for characterization and targeting of epigenetically mediated resistance mechanisms in PDAC.

cancer biology↗